The chemotherapeutic CX-5461 primarily targets TOP2B and exhibits selective activity in high-risk neuroblastomaMin Pan, Paul Geeleher|Nature Communications|2021Cited by 90
An open-source screening platform accelerates discovery of drug combinationsWilliam C. Wright, Paul Geeleher, Duane Currier et al.|Nature Communications|2025Cited by 3
Abstract 1907: Combocat: A high-throughput framework for drug combination studiesWilliam C. Wright, Paul Geeleher, Min Pan et al.|Cancer Research|2022Cited by 0